Evidence map›Paper›PMID 40715467›Full record

ArticleBJC reports2025

Monoclonal antibody for phosphorylated TRIO Y2681 that helps predict prognosis of post-operative colorectal cancer patients.

Taro Aoyama, Fumihiko Kakizaki, Hiroyuki Miyoshi, Masahiro Sonoshita, Hisatsugu Maekawa, Yoshiro Itatani, Kenji Kawada, Ryo Matsusue, Iwao Ikai, Koki Moriyoshi and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJC reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Taro AoyamaColon Cancer Project, Kyoto University Hospital-iACT, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Fumihiko KakizakiColon Cancer Project, Kyoto University Hospital-iACT, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hiroyuki MiyoshiColon Cancer Project, Kyoto University Hospital-iACT, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Masahiro SonoshitaDivision of Biomedical Oncology, Institute for Genetic Medicine, Hokkaido University, Hokkaido, Japan.
Hisatsugu MaekawaDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yoshiro ItataniDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kenji KawadaDepartment of Surgery, Kurashiki Central Hospital, Okayama, Japan.
Ryo MatsusueDepartment of Gastroenterological Surgery, Tenri Hospital, Nara, Japan.
Iwao IkaiDepartment of Surgery, Koseikai Takeda Hospital, Kyoto, Japan.
Koki MoriyoshiDepartments of Diagnostic Pathology, Kyoto Medical Center, National Hospital Organization, Kyoto, Japan.
Takaki SakuraiDepartment of Pathology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
Kazutaka ObamaDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Tosiya Shun SatoInstitute of Statistical Mathematics, and Data Science and AI Innovation Research Promotion Center, Shiga University, Shiga, Japan.
Yoshiharu SakaiDepartment of Surgery, Japanese Red Cross Osaka Hospital, Osaka, Japan.
Makoto Mark TaketoColon Cancer Project, Kyoto University Hospital-iACT, Graduate School of Medicine, Kyoto University, Kyoto, Japan. taketo@mfour.med.kyoto-u.ac.jp.

Funding

Japan Agency for Medical Research and Development ck0106195hJapan Science and Technology Agency ST261001TT
6 · The paper itself

Abstract

backgroundWe previously reported that TRIO pY2681, a novel prognostic biomarker for CRC, can be detected by polyclonal antibodies (pAb). We have now developed a novel monoclonal antibody (mAb) that recognizes TRIO pY2681. This study aims to assess the utility of immunohistochemical (IHC) staining using the TRIO pY2681 mAb as a prognostic marker for CRC in clinical practice.

methodsIHC using TRIO pY2681 mAb was performed on surgical specimens from 357 CRC patients at Kyoto Medical Center and 320 at Kyoto University Hospital. Based on the results, we conducted a retrospective outcome analysis.

resultsTRIO pY2681 mAb exhibited significantly higher titers than pAb. In both cohorts of all stages, TRIO pY2681 IHC positivity correlated with shorter disease-specific survival (DSS) (HR, 1.67; 95% CI, 1.00-2.79; P = 0.046, and HR, 5.84; 95% CI, 2.26-15.1; P < 0.001) and relapse-free survival (RFS) (HR, 1.92; 95% CI, 1.15-3.22; P = 0.011, and HR, 4.36; 95% CI, 2.17-8.76; P < 0.001). The trend persisted in stage III. Multivariate analysis confirmed TRIO pY2681 IHC positivity as an independent prognostic factor for RFS.

conclusionsThe novel TRIO pY2681 mAb identifies CRC patient subsets with poorer prognoses, enhancing prognostic precision in clinical settings.

Identifiers

PMID40715467
PMCPMC12297228

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.